Success Metrics

Clinical Success Rate
81.8%

Based on 9 completed trials

Completion Rate
82%(9/11)
Active Trials
0(0%)
Results Posted
78%(7 trials)
Terminated
2(18%)

Phase Distribution

Ph phase_1
2
18%
Ph phase_2
4
36%
Ph not_applicable
1
9%
Ph phase_3
4
36%

Phase Distribution

2

Early Stage

4

Mid Stage

4

Late Stage

Phase Distribution11 total trials
Phase 1Safety & dosage
2(18.2%)
Phase 2Efficacy & side effects
4(36.4%)
Phase 3Large-scale testing
4(36.4%)
N/ANon-phased studies
1(9.1%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

81.8%

9 of 11 finished

Non-Completion Rate

18.2%

2 ended early

Currently Active

0

trials recruiting

Total Trials

11

all time

Status Distribution
Completed(9)
Terminated(2)

Detailed Status

Completed9
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
11
Active
0
Success Rate
81.8%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (18.2%)
Phase 24 (36.4%)
Phase 34 (36.4%)
N/A1 (9.1%)

Trials by Status

terminated218%
completed982%

Recent Activity

0 active trials
Showing 5 of 11
completedphase_2

Evaluation of Alisporivir for the Treatment of Hospitalised Patients With Infections Due to SARS-CoV-2 (COVID-19)

NCT04608214
terminatedphase_3

Alisporivir (Deb025) and Boceprevir Triple Therapies in African American Participants Not Previously Treated for Chronic Hepatitis C Genotype 1

NCT01446250
completedphase_2

Alisporivir With RBV in Chronic Hepatitis C Genotype 2 and 3 Participants for Whom Interferon is Not an Option

NCT02094443
completedphase_3

Efficacy and Safety of Alisporivir Triple Therapy in Chronic Hepatitis C Genotype 1 Treatment-naïve Participants

NCT01318694
completedphase_2

Efficacy and Safety of Alisporivir Alone or Combined With RBV or PEG in Chronic Hepatitis C Genotype 2 and 3 Treatment-naïve Participants

NCT01215643
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT04608214Phase 2

Evaluation of Alisporivir for the Treatment of Hospitalised Patients With Infections Due to SARS-CoV-2 (COVID-19)

Completed
NCT01446250Phase 3

Alisporivir (Deb025) and Boceprevir Triple Therapies in African American Participants Not Previously Treated for Chronic Hepatitis C Genotype 1

Terminated
NCT02094443Phase 2

Alisporivir With RBV in Chronic Hepatitis C Genotype 2 and 3 Participants for Whom Interferon is Not an Option

Completed
NCT01318694Phase 3

Efficacy and Safety of Alisporivir Triple Therapy in Chronic Hepatitis C Genotype 1 Treatment-naïve Participants

Completed
NCT01215643Phase 2

Efficacy and Safety of Alisporivir Alone or Combined With RBV or PEG in Chronic Hepatitis C Genotype 2 and 3 Treatment-naïve Participants

Completed
NCT02753699Phase 3

Long Term Follow-up Study to Assess Durability of Sustained Virologic Response in Alisporivir-treated Hepatitis C Patients

Completed
NCT01183169Phase 2

Efficacy and Safety of Adding Alisporivir (DEB025) to Peginterferon (IFN) Alfa-2a (Peg-IFN Alfa-2a) and Ribavirin in Chronic HCV Genotype 1 Patients Who Relapsed or Did Not Respond to Previous Treatment

Completed
NCT01975337Phase 1

Pharmacokinetics and Safety of Alisporivir in Subjects With End Stage Renal Disease on Hemodialysis Compared to Healthy Subjects

Completed
NCT01500772Phase 3

Alisporivir With PEG and RBV in Protease Inhibitor (PI) Treatment Failure Patients With Chronic Hepatitis C

Terminated
NCT01860326Phase 1

Evaluate the Pharmacokinetics, Safety, and Tolerability of Alisporivir in Subjects With Hepatic Impairment Compared to Healthy Subjects

Completed
NCT01970904Not Applicable

Pharmacokinetics, Pharmacodynamics and Safety of DEB025 Plus Ribavirin in Chronic Hepatitis C Genotype 2 and 3 Treatment naïve Patients

Completed

All 11 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
11